miochol-e 10 mg/ml jauhe ja liuotin instillaatioliuosta varten, silmän sisään
dr. gerhard mann chem.-pharm. fabrik gmbh - acetylcholine chloride - jauhe ja liuotin instillaatioliuosta varten, silmän sisään - 10 mg/ml - asetyylikoliini
ketosteril tabletti, kalvopäällysteinen
fresenius kabi ab - histidine, lysine acetate, threonine, tryptophane, tyrosine, alpha-ketoleucine calcium, alpha-ketophenylalanine calcium, alpha-ketovaline calcium, d,l-alpha-hydroxymethionine calcium, d,l-alpha-ketoisoleucine calcium - tabletti, kalvopäällysteinen - aminohapot
ultomiris
alexion europe sas - ravulizumab - hemoglobinuria, paroxysmal - selektiiviset immunosuppressantit - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
vyvgart
argenx - efgartigimod alfa - myasthenia gravis - immunosuppressantit - vyvgart is indicated as an add on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti acetylcholine receptor (achr) antibody positive.
oriprim vet jauhe
orion corporation - sulfadiazine, trimethoprim - jauhe - sulfadiatsiini ja trimetopriimi
reodyn 50 mg/ml oraaliliuos
orion corporation - carbocysteine - oraaliliuos - 50 mg/ml - karbosisteiini
mesalazin orion 500 mg enterotabletti
faes farma, s.a. - mesalazine - enterotabletti - 500 mg - mesalatsiini
mesalazin orion 1000 mg enterotabletti
faes farma, s.a. - mesalazine - enterotabletti - 1000 mg - mesalatsiini